How hot is Hong Kong's biotech IPO market? Two biotechs just raised $800M total

A pair of Chinese biotechs have collectively hauled in close to $800 million upon their public debuts in Hong Kong, tucking two hefty entrants to the steady stream of HKEX IPOs. Everest Medicines raised $423 million to bankroll its pipeline of in-licensed drugs, while Genor Biopharma is pouring its $371 million proceeds into the cancer and autoimmune pipeline.